67643-16-7

Basic information

• Product Name: 4H-Pyran-3-carbonitrile,2-amino-6-methyl-4-oxo-(9CI)
• Synonyms: 4H-Pyran-3-carbonitrile,2-amino-6-methyl-4-oxo-(9CI);4H-Pyran-3-carbonitrile, 2-aMino-6-Methyl-4-oxo-;2-Amino-6-methyl-4-oxo-4H-pyran-3-carbonitrile
• CAS NO: 67643-16-7
• Molecular Formula: C₇H₆N₂O₂
• Molecular Weight: 150.13474
• Product Categories: AMINEPRIMARY
• Mol File: 67643-16-7.mol

Chemical Properties

• Melting Point: 275 °C (decomp)
• Boiling Point: 381℃
• Flash Point: 184℃
• Appearance: /
• Density: 1.32
• PKA: 0.03±0.40(Predicted)
• CAS DataBase Reference: 4H-Pyran-3-carbonitrile,2-amino-6-methyl-4-oxo-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-Pyran-3-carbonitrile,2-amino-6-methyl-4-oxo-(9CI)(67643-16-7)
• EPA Substance Registry System: 4H-Pyran-3-carbonitrile,2-amino-6-methyl-4-oxo-(9CI)(67643-16-7)

Safety Data

• Hazardous Substances Data: 67643-16-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4H-Pyran-3-carbonitrile,2-amino-6-methyl-4-oxo-(9CI) is used as a key intermediate in the synthesis of various organic compounds due to its reactive functional groups. Its presence in the molecular structure allows for the formation of new chemical bonds and the creation of diverse organic molecules with potential applications in various industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4H-Pyran-3-carbonitrile,2-amino-6-methyl-4-oxo-(9CI) is used as a building block for the development of novel drug candidates. Its unique structure and reactivity enable the design and synthesis of new pharmaceutical compounds with potential therapeutic effects. Further research and analysis are required to explore its full potential in drug discovery and development.
Used in Chemical Research:
4H-Pyran-3-carbonitrile,2-amino-6-methyl-4-oxo-(9CI) serves as an important subject of study in chemical research, providing insights into the properties and behavior of pyran-3-carbonitrile compounds. Its unique structure and reactivity make it an interesting target for future research and development, potentially leading to the discovery of new chemical reactions, mechanisms, and applications in various fields.

Upstream product

• 674-82-8 4-methyleneoxetan-2-one 
• 109-77-3 malononitrile 
• 15456-25-4 3-methylenecyclobutanone 
• 2911-22-0 6-methyl-4-oxo-2-thioxo-3,4-dihydro-2H-1,3-oxazine 
• 15159-48-5 2,4-oxetanedione 

Downstream Products

• 38367-36-1 2,4-dichloro-6-methyl-3-pyridinecarbonitrile 
• 4241-27-4 1,2-dihydro-6-methyl-2-oxo-3-pyridinecarbonitrile 
• 582300-58-1 4-chloro-1,2-dihydro-6-methyl-2-oxo-3-pyridinecarbonitrile 
• 1802175-06-9 (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole-3-carboxamide 
• 1802175-06-9 (S)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole-3-carboxamide 
• 1450654-49-5 N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole-3-carboxamide 
• 1438382-15-0 3-(aminomethyl)-4-methoxy-6-methylpyridin-2(1H)-one 
• 1802175-07-0 CPI-169 
• 1450662-06-2 ((2,4-dimethoxy-6-methylpyridin-3-yl)methyl)carbamic acid tert-butyl ester 
• 1450662-05-1 2,4-dimethoxy-6-methylnicotinonitrile 

Relevant articles and documents

1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.

Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents

Zeste enhancer homolog 2 (EZH2) is highly expressed in various malignant tumors, which could silence tumor suppressor genes via trimethylation of H3K27. Herein was first reported a novel series of pyrrole-3-carboxamide derivatives carrying a pyridone fragment as EZH2 inhibitors. By combining computational modeling, in vitro cellular assays and further rational structure-activity relationship exploration and optimization, compound DM-01 showed powerful inhibition towards EZH2. DM-01 was found to have significant ability to reduce the cellular H3K27me3 level in K562 cells in the Western blot test. Meanwhile, our data showed that knockdown EZH2 in A549 cells resulted in a decrease of cell sensitivity to DM-01 at 50 and 100 μM. DM-01 could also increase the transcription expression of DIRAS3 in a dose-dependent manner, a tumor suppressor in the downstream of EZH2, suggesting it was worth investigating further as a lead compound.

5-Hydroxyindole-based EZH2 inhibitors assembled via TCCA-catalyzed condensation and Nenitzescu reactions

5-Hydroxyindole derivatives have various demonstrated biological activities. Herein, we used 5-hydroxyindole as a synthetic starting point for structural alterations in a combinatorial process to synthesize 22 different compounds with EZH2 inhibitor pharmacophores. A series of 5-hydroxyindole-derived compounds were screened inhibitory activities against K562 cells. According to molecular modeling and in vitro biological activity assays, the preliminary structure-activity relationship was summarized. Compound L–04 improved both the H3K27Me3 reduction and antiproliferation parameters (IC50 = 52.6 μM). These findings revealed that compound L–04 is worthy of consideration as a lead compound to design more potent EZH2 inhibitors. During the preparation of compounds, we discovered that trichloroisocyanuric acid (TCCA) is a novel catalyst which demonstrates condensation-promoting effects. To gain insight into the reaction, in situ React IR technology was used to confirm the reactivity. Different amines were condensed in high yields with β-diketones or β-ketoesters in the presence of TCCA to afford the corresponding products in a short time (10~20 min), which displayed some advantages and provided an alternative condensation strategy.

4,5,6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

Provided are 4,5,6-tri-substituted indazoles derivatives, a preparation method therefor, and a use thereof in medicines. Specifically, provided are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates, or prodrugs thereof

SULFONYL-SUBSTITUTED BENZOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF

The present invention relates to a sulfonyl-substituted benzoheterocyclic derivative, a preparation method and medical use thereof. Particularly, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a preparation method and application thereof. The definition of each group in the formula can be found in the specification and the claims.

INHIBITORS OF EZH2

The present invention relates to compounds that inhibit activity of the histone lysine methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors.

IMIDAZOPYRIDINE EZH2 INHIBITORS

The present invention relates to imidazopyridines of general formula (I), to a method for their preparation, to intermediates for their preparation, to pharmaceutical compositions comprising at least one of those compounds, and to the use thereof.

Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitabl

Polycomb repressive complex 2 (PRC2) has been shown to play a major role in transcriptional silencing in part by installing methylation marks on lysine 27 of histone 3. Dysregulation of PRC2 function correlates with certain malignancies and poor prognosis

Modulators of methyl modifying enzymes, compositions and uses thereof

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.

INDOLE DERIVATIVES AS MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF

Agents of formulas (l)/(ll)/(lll) for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.